Written by: Katie Carter, PharmD, BCPS, Indiana University Health
Download Here

Olaparib (Lynparza) is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is currently FDA approved as targeted therapy for BRCA-mutated breast cancer and ovarian cancer.  This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.
Continue reading Olaparib in BRCA-mutated Breast, Ovarian and Pancreatic Cancer

Read More

Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.  Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication.
Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More

Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch
Download Here

Venetoclax (Venclexta) therapy requires particular parameters be closely followed to ensure optimal patient outcomes.  This PQI will review appropriate risk stratification, dosing, and dispensing procedures.   These risk stratifications create special challenges for the dispensing of venetoclax.   Some medium-risk and all high-risk patients may require hospital admission during titration; communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient will ensure the recommended administration guidelines and lab monitoring are followed to ensure patient safety and best outcomes.

Continue reading Venetoclax Risk Stratification, Dosing, and Dispensing Procedure

Read More

Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

For patients with Non‐Small Cell Lung Cancer (NSCLC) that have sensitizing epidermal growth factor receptor (EGFR) mutations (most commonly exon 19 deletions or exon 21 L858R mutations) appropriate for first‐line treatment with an EGFR inhibitor, osimertinib (Tagrisso) has a clear progression free survival (PFS) benefit compared to chemotherapy and has been recently recommended as a preferred first line agent according to the NCCN guidelines. If another EGFR inhibitor is being prescribed for a patient with a sensitizing EGFR mutation, the pharmacist will contact the Physician to determine why the current therapy was chosen.

Continue reading EGFR Inhibitors

Read More

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis. The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse. Testing rates at diagnosis and especially relapse are low. Venetoclax is approved in patients who have relapsed after one therapy and have the 17p deletion. Continue reading CLL and Del17P

Read More